: In our clinical case, the patient, affected by morphea, reported an excellent response to the administration of baricitinib 4 mg day-1, with rapid disappearance of itching and reduction of the erythematous-infiltrative component of the plaques, highlighting the important role of the JAK/STAT pathway in TGF-β-mediated profibrotic signalling.
Baricitinib improved morphoea manifestations in a patient with alopecia areata universalis / Rubino, Vincenzina; Baffa, Maria E; Pipitò, Carlo; Savian, Samuele; Senatore, Stefano; Maglie, Roberto; Antiga, Emiliano. - In: SKIN HEALTH AND DISEASE. - ISSN 2690-442X. - ELETTRONICO. - 5:(2025), pp. 495-496. [10.1093/skinhd/vzaf071]
Baricitinib improved morphoea manifestations in a patient with alopecia areata universalis
Rubino, Vincenzina
;Baffa, Maria E;Pipitò, Carlo;Savian, Samuele;Maglie, Roberto;Antiga, Emiliano
2025
Abstract
: In our clinical case, the patient, affected by morphea, reported an excellent response to the administration of baricitinib 4 mg day-1, with rapid disappearance of itching and reduction of the erythematous-infiltrative component of the plaques, highlighting the important role of the JAK/STAT pathway in TGF-β-mediated profibrotic signalling.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Skin Health Dis 2025 Morphea AA baricitinib.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
744.93 kB
Formato
Adobe PDF
|
744.93 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
